GCTK — GlucoTrack Inc
NASDAQ · Healthcare · Medical Instruments & Supplies
$3.68
-$0.57 (-13.41%)
GlucoTrack Inc (GCTK) is a medical instruments & supplies company listed on NASDAQ. It is led by Paul V. Goode Ph.D., based in 301 Route 17 North, Rutherford, NJ, United States, 07070, with about 15 employees. GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Net income was -$4.2M. GCTK currently screens at market cap $4.1M and trailing P/E 0.1.
On the latest cached filing, GCTK: Accountant’s Review Report (8-K 2026-08-28). Why it matters: expects to continue to incur substantial losses in the future. As of June 30, 2026, the Company had cash and cash equivalents This GCTK stock page is the analysis view: what changed in the numbers, and why it matters for GlucoTrack Inc.
Use this GCTK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GCTK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GCTK SEC filings page. Lician reads the product cache first so this HTML stays unique to GlucoTrack Inc even when a live quote feed is slow.
What changed in GCTK
8-K · 2026-08-28
GCTK: Accountant’s Review Report
Why it matters
- expects to continue to incur substantial losses in the future. As of June 30, 2026, the Company had cash and cash equivalents
About GlucoTrack Inc
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
GCTK Key Statistics
Market Cap
$4.13M
Volume
566,270
Previous Close
$0.34
Day Range
$0.32 – $0.35
P/E Ratio
0.11
EPS
$68.44
Revenue
$0.00
Net Income
-$22.60M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
15
GCTK Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$22.60M | -$7.10M | -$4.43M | -$4.07M |
| EPS (Diluted) | $68.44 | $34.18 | $0.29 | $0.26 |
Total Assets
$5.93M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.62M
Operating Cash Flow
-$12.49M
Free Cash Flow
$0.00
GlucoTrack Inc Company Information
- CEO, President & Director
- Paul V. Goode Ph.D.
- Headquarters
- 301 Route 17 North, Rutherford, NJ, United States, 07070
- Website
- glucotrack.com
- Phone
- 201 842 7715
- IPO / Founded
- 2013-04-25
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies